Autonomix Raises $2.6M via Warrant Exercise, Issues New Warrants at Market
AMIX sits 37% above its 52-week low of $4.204 on elevated volume (34× avg).
Summary
Autonomix Medical entered a warrant inducement deal, raising $2.6M in gross proceeds from the immediate exercise of existing warrants at a reduced $6.00 strike price. The company is also issuing new Series D-1 and D-2 warrants to purchase 428,731 shares each at $5.75, exercisable immediately and expiring in five and a half years. The transaction is priced at-the-market under Nasdaq rules, avoiding a discount that would signal distress. This follows the company's recent 1-for-21 reverse split and regained Nasdaq compliance, suggesting ongoing efforts to manage its capital structure. The modest raise provides near-term funding for its early-stage medical device platform.
At the time of this announcement, AMIX was trading at $5.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1M. The 52-week trading range was $4.20 to $55.44. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.